Atypical Symptoms and High Mortality Associated
Background. Meningococcal disease occurs in an endemic or epidemic form, such as meningitis or meningococcemia, the latter being a fast and high disease, mainly in children. Atypical symptoms have been described by the serogroup W. The aim of this study was to determine the clinical and epidemiological characteristics of invasive meningococcal disease (IMD) by serogroup B and the factors associated with mortality in the Cartagena, Colombia between 2012 and 2016.
Methods. Cross-sectional study, carried out from 2012 to 2016 in patients diagnosed with meningococcal disease. Measures of central tendency and dispersion were calculated. A bivariate analysis was performed comparing deceased patients with survivors.
Results. From January 2012 to December 2016, a total of 41 cases were reported: one suspected, seven probable, and 33 confirmed cases (all serogroup B), which 73.2% were male, average age 17. Conclusion. Atypical gastrointestinal manifestations, besides being described by serogroup W, may also be a form of presentation of serogroup B, related to a higher mortality.
Disclosures. Background. This study's aim was to compare pathogen identification (ID) and antimicrobial susceptibility testing (AST) result turnaround times of the Accelerate Pheno™ system (AXDX) against current standard methods (SOC). Secondarily, we assessed whether its implementation for positive blood cultures (PBC) with monomicrobial Gram-negative bacilli could provide theoretical improvement in time to active and optimal antibiotic therapy.
Methods. Over 3 months, Gram-negative PBC from 114 patients, including 29 pediatric patients, were identified for the study. Blood cultures were tested on both the Verigene® and AXDX platforms in tandem after flagging positive on the BACTEC® FX system. Isolates were tested on the Bruker MALDI Biotyper® system for ID and VITEK® 2 system (GN73 cards) for AST. Patient charts were then retrospectively evaluated to calculate time to active and optimal therapy. On comparing time to results (ID and AST) for AXDX with SOC, timing calculations to mimic setup and reporting times for tests and results were included.
Results. From time of blood culture positivity, mean time to ID averaged 36.3 hours for MALDI-TOF MS, 4.5 hours for the Verigene® system and 3.6 hours for AXDX, while the mean time to AST averaged 35.8 hours for the VITEK ® 2 system and 8.9 hours for AXDX. Thirty-nine percent (45/114) of patients were not on active therapy at time of positive blood culture. Of these, 29 were put on active therapy within a mean of 21 hours (range: 9.3 hours to 5.6 days), such that 25% of patients could have been put on active therapy sooner had AXDX AST results been available clinically for action by a physician or stewardship team. Similarly, 34 were put on optimal therapy within a mean of 1.3 days (range: 9.3 hours to 5.6 days). Thus, 30% of patients could have had therapy optimized earlier had AXDX AST results been available.
Conclusion. Overall, the Accelerate Pheno™ system is a reliable new diagnostic modality that has the potential to significantly reduce time to PBC ID and AST results, as well as time to active and optimal therapy, thus aiding in effective antimicrobial stewardship. Prospective studies evaluating the clinical impact of AXDX on patient outcomes are needed and planned.
Disclosures. J. Schneider, Accelerate Diagnostics: Investigator, kits and data management and Research support. Background. Most phenotypic methods routinely employed for the detection of ESBL and AmpC producing Enterobacteriaceae require 18 hours of incubation. Aiming to offer this clinically relevant information in a shorter time, we developed a MALDI-TOF MS-based direct-on-target microdroplet growth assay (DOT-MGA) as a one-step screening and confirmation panel in accordance with the EUCAST guidelines.
Validation of a MALDI-TOF MS-Based Direct-on-Target Microdroplet Growth Assay (DOT-MGA) for Rapid Detection of Extended-Spectrum β-Lactamase (ESBL) and AmpC in Clinical Enterobacteriaceae
Methods. DOT-MGA was performed on 12 clinical Enterobacteriaceae strains displaying resistance against third-generation cephalosporins plus four control strains recommended by EUCAST for detection of ESBL production. Microdroplets (6 µL) containing bacterial suspension and antibiotics (cefpodoxime, cefotaxime, ceftazidime, cefepime with or without clavulanic acid, and/or cloxacillin) in cation-adjusted Mueller-Hinton broth (CA-MHB) were spotted directly onto MBT Biotargets 96 (Bruker Daltonics, Germany). Targets were incubated for 4 hours at 36°C in plastic transport boxes in order to avoid evaporation. Subsequently, culture medium was removed and MALDI-TOF MS of the cells adhered to the target's surface was performed. The minimum inhibitory concentration (MIC) was considered to be the lowest concentration at which the MALDI Biotyper software (Bruker) provided no species identification. ESBL/AmpC production was defined as an 8-fold or greater decrease of the cephalosporin MIC when combined with clavulanic acid and/or cloxacillin, respectively. A computer-based algorithm was established to interpret the results, which were compared with those of broth microdilution (reference method). Resistance mechanisms of the clinical isolates were assessed by PCR.
Results. The method correctly identified the ESBL and AmpC production of both control and clinical strains (positive agreement, 100%; negative agreement, 100%), allowing the differentiation of each mechanism even in isolates displaying combined resistance. The results agreed with the characterization of the strains by PCR.
Conclusion. We present a rapid method for phenotypic detection of ESBL and AmpC that yields reliable results in a significantly shorter time, thus representing a potentially valuable tool in the routine detection of multidrug-resistant pathogens.
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